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We already reported the use of a long synthetic signal peptide (LSSP) to secrete the Streptomyces sp. TO1 amylase by Streptomyces
lividans strain. We herein report the expression and secretion of the rat CD11b A-domain using the same LSSP and S. lividans as
host strain. We have used the Escherichia coli/Streptomyces shuttle vector pIJ699 for the cloning of the A-domain DNA sequence
downstream of LSSP and under the control of the constitutive ermE-up promoter of Streptomyces erythraeus. Using this construct
and S. lividans as a host strain, we achieved the expression of 8mg/L of soluble secreted recombinant form of the A-domain of
the rat leukocyte β2 integrin CD11/CD18 alpha M subunit (CD11b). This secreted recombinant CD11b A-domain reacted with a
function blocking antibody showing that this protein is properly folded and probably functional. These data support the capability
of Streptomyces to produce heterologous recombinant proteins as soluble secreted form using the “LSSP” synthetic signal peptide.
Copyright © 2007 Dorra Zouari Ayadi et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1. INTRODUCTION
Streptomyces species are saprophytic gram-positive soil bac-
teria that posses a large range of extracellular hydrolytic
enzymes such as α-amylases, agarases, cellulases, xylanases,
nucleases, and lipases [1]. The potential of S. lividans,a sa
host for the expression of heterologous recombinant bac-
terial and eukaryotic proteins, has extensively been investi-
gated [2]. Indeed, this microorganism has several features
that make it a suitable host for eﬃcient recombinant pro-
tein expression among which are the well-established genetic
manipulationprocedures[3]andtheabsenceofextensivere-
striction modiﬁcation systems that are generally present in
other Streptomyces species. Furthermore, S. lividans has very
low endogenous extracellular proteolytic activity when com-
pared to other Streptomyces species [4] and does not elicit
the formation of inclusion body of recombinant protein in
the cytoplasm, a problem encountered in the majority of the
expression systems used for eukaryotic and prokaryotic pro-
teins in E. coli. Indeed, overproduction of some proteins in
E. coli led to their incorporation into insoluble inclusions
bodies.Whileitispossibletosolubilizetheinclusionsbodies,
there is no guarantee that attempted renaturation will lead to
signiﬁcant level of active protein. The high level of solubility
is a general characteristic of proteins made in Streptomyces
[3]. For these diverse reasons, S. lividans is the host of choice
for the secretory production of heterologous proteins and a
very attractive biotechnology platform.
Over the past two decades, a growing number of studies
have demonstrated that S. lividans is a model host for the
production of secreted heterologous recombinant proteins
[5–12]. In most cases, genes of interest were fused to well-
characterized signal peptide sequences of naturally highly se-
creted Streptomyces proteins [11, 13, 14]. Alternatively, syn-
thetic signal peptides were used such as the 35 amino acids
long synthetic signal peptide (LSSP) that we have previously
usedsuccessfullyforthesecretionoftheStreptomycessp.TO1
amylase [10] which is a naturally secreted protein. This sig-
nalpeptidewasdeducedbyalignmentofseveralStreptomyces
signal peptides and carried an additional ribosome binding
site as well as a second initiation codon. The addition of a
second ribosome binding site and a second initiation codon2 Journal of Biomedicine and Biotechnology
increasedtheyieldofsecretedproteinaccordingtoPag´ eetal.
[15].
Several Streptomyces secretion systems have successfully
been developed for the production of eukaryotic proteins es-
pecially those of medical interest [9]. For examples, we can
mention the eﬃcient production in S. lividans of the murine
tumor necrosis factor (TNF) alpha fused to the secretory sig-
nalpeptideofthesubtilisininhibitorproteinfrom Svenezue-
lae [8, 16]. Expression of biologically active human inter-
feron alpha 2 was also achieved in S. lividans [17].
Theβ2integrins(CD11/CD18)aresurfaceheterodimeric
glycoproteins and represent one of the most important fami-
lies of theleucocytesadhesion molecules. This family iscom-
posed of 4 glycoprotein complexes each one consists in an
α/β heterodimer containing two distinct chains: the alpha
(CD11a, CD11b, CD11c, and CD11d) and the beta (CD18)
subunits. They have a widespread vital function in devel-
opment, embryogenesis, tissue organization, wound heal-
ing and immune response [18]. The β2 integrins recog-
nize multiple ligands and mediate several important cell-
substrate and cell-cell adhesive interactions. Binding of in-
tegrins to their physiological ligands is a dynamic, divalent
cation-dependent, and tightly regulated process. The α sub-
units display an A-domain in their amine termini that me-
diates proinﬂammatory functions [19]. These are mainly
the adhesive interaction with vascular endothelial cells that
lead to leukocyte transmigration and diapedesis [20]. The
A-domain of the αM subunit (CD11b) of the rat leuko-
cyte β2 integrin CD11/CD18, which was used for this work,
was already cloned and expressed in E. coli in the intracel-
lular compartment as a soluble recombinant fusion protein
withGST.RecombinantCD11bA-domainwasreleasedfrom
the fusion protein by thrombin cut. This recombinant do-
main retained its adhesive function as shown by its bind-
ing in vitro with members of the immunoglobulin super-
family [20]. Furthermore it was used to demonstrate that
it is capable to protect the skeletal muscle from inﬂamma-
tory injury in vivo using a rat model of crush syndrome
[21]. In this paper, we report for the ﬁrst time the heterol-
ogous expression and eﬃcient secretion, by S. lividans, of the
soluble recombinant rat CD11b A-domain; using the con-
stitutive ermE-up promoter (PermE) from Streptomyces ery-
thraeus [22] and the long synthetic signal peptide (LSSP)
[10].
2. MATERIAL AND METHODS
2.1. Bacterialstrainsandmedia
S. lividans 1326 was used as a host cell for transforma-
tion. Protoplasts preparation and transformation procedures
were performed as described by Hopwood et al. [23]. The
R2YE medium was used for protoplasts regeneration and
thiostrepton (the antibiotic selection marker carried by the
E. coli/Streptomyces shuttle vector pIJ699 [24]) was added at
50μg/mL for selection of transformed S. lividans cells. For
growth of S. lividans harbouring pMS115, thiostrepton was
addedataconcentrationof15 μg/mLinliquidmediumorat
20μg/mL in solid medium and cultures were grown on TSB
or NMMP media [23]a t3 0 ◦C for 48h with shaking.
E. coli strains used were TOP10 for cloning of PCR
products into pCR-Blunt vector (Invitrogen) and DH5α as
host strain for plasmid propagation. Cultures were grown at
37◦C in Luria-Bertani medium in the presence of ampicillin
(50μg/mL) when required.
2.2. Plasmidsandcloningprocedures
The 276bp SacI-BamHI fragment from pIJ4070 harbouring
the constitutive ermE-up promoter [22]w a ss u b c l o n e di n
the pMS39 plasmid [10] carrying the long synthetic signal
peptide (LSSP) giving the pMS41 plasmid. Then the 410bp
KpnI-HincII fragment (PermE-up-LSSP) from pMS41 was
cloned in the KpnI-HincII sites of pIJ4070 yielding the
pMS51 plasmid (PermE-up-LSSP).
The sequence coding for the A-domain of the rat
leukocyte β2 integrin CR3 alphaM subunit (CD11b) was
ampliﬁed by PCR using the following two primers: S43
5 -CTCGATATCTGTCCTCAGCAGGAGAGCAAC-3  har-
bouring an EcoRV site and S44 5 -CTCTGCAGCGTCAGT-
CAGTCACGAT-3  harbouringaPstIsiteandastemplatethe
pGEX-2T plasmid containing the CD11b A-domain fused to
the glutathione S-transferase (GST) [20]. (PCR conditions
were 5min at 94◦Cf o l l o w e db y3 5c y c l e so f3 0sa t9 4 ◦C, 45s
at 68◦C, and 35s at 72◦C. Ampliﬁcation was carried out us-
ing the Pfu DNA polymerase from Stratagene.) The 622bp
PCR fragment corresponding to the A-domain coding se-
quence was cloned into the pCR-Blunt vector to produce
the pMS52 plasmid. Then the 610bp EcoRV-PstIf r a g m e n t
from pMS52 was cloned in the EcoRV-PstI sites of pMS51
giving the pMS62 plasmid. Finally, the 1030bp BglII frag-
ment from pMS62 carrying the cassette “PermE-up-LSSP-A-
domain” was ligated to the pIJ699 vector cut by BglII [24].
After transformation of the S. lividans 1326 protoplasts, the
recombinant strain carrying the resulting pMS115 plasmid
was called S. lividans 1326/pMS115.
2.3. DNAisolationandmanipulation
PlasmidpreparationandDNAmanipulationfromtheS.livi-
dans1326/pMS115strainwerecarriedoutaccordingtoHop-
wood et al. [23]a n df r o mE. coli as described by Sambrook
et al. [25].
2.4. RNAisolationandRT-PCR
The S. lividans 1326/pMS115 strain was precultured at 30◦C
on TSB medium [23] then inoculated at 1/10 in the same
conditions. Cultures were stopped at the end of the expo-
nential phase (36h), early stationary phase (50h), and late
stationaryphase(60h).Thenthecellswereharvestedbycen-
trifugation(7500xg,for15minat4◦C).RN A sw er epr epar ed
from these cultures as described by Hopwood et al. [23]e x -
cept that a DNase I (Promega) treatment was used in addi-
tion to salt precipitation. This RNA preparation was used in
RT-PCRexperiments.cDNAcorrespondingtotheA-domainDorra Zouari Ayadi et al. 3
wassynthesizedfromtheisolatedRNAs(treatedwithDNase)
using the AMV reverse transcriptase (AMV-RT) from Amer-
sham as follows: 2μLo fR N A( 2μg), 2.5μL of primer S259
at 10μM, and 9μLH 2O RNase-free. Reactions were incu-
bated in a thermocycler at 65◦Cf o r5m i nt h e np l a c e do ni c e
and the following components were added in each sample:
4μLofAMV -R T5xbuﬀer,1μLofAMV-RT(1U/μL),1μLof
RNasin (Amersham), and 0.5μL of dNTP 10mM each. Re-
actions were incubated at 42◦C for 90min and then at 70◦C
for 15min.
10% of the synthesized cDNA (2μL) was ampliﬁed by
PCR using the internal primers S258-forward, 5 -CAGGA-
GAGCAACATTGCCTTC-3 , and S259-reverse, 5 -GTGAT-
CACCAGCTGGCTTAGA-3 .Ascontrol,wehaveperformed
a PCR reaction using as matrix 1μgo fR N At r e a t e dw i t h
DNase. The cycling parameters were 94◦Cf o r5 m i n ,f o l -
lowed by 35 cycles of 94◦C for 30s, 52◦Cf o r4 5s ,a n d7 2 ◦C
for 30s. In all cases, 10μLf r o m5 0μL of the PCR reactions
were analyzed on a 1.2% agarose gel.
2.5. Westernblotanalysis
S. lividans 1326/pMS115 strain was precultured on TSB
medium then inoculated at 1/10 in NMMP medium [23]
with of 1% (W/V) of glucose and grown for 48h at 30◦C. Af-
terculturecentrifugation(7500xg,for15minat4◦C),super-
natant was lyophilized, resuspended in a minimum amount
of phosphate buﬀered saline (PBS) at pH 7.4, and then dia-
lyzed for 24h at 4◦C against the same buﬀer.
ProteincontentwasdeterminedusingBradford’smethod
with serum albumin as the standard.
15μgo fs e c r e t e dp r o t e i n sw e r el o a d e da n dr e s o l v e do na
15% SDS denaturing polyacrylamide gel run in a Tris glycine
electrophoresis buﬀer as described by Laemmli [26].
The GST/CD11b A-domain fusion protein and the A-
domain released from the fusion protein by thrombin cut
were used as controls [20]. The gel was transferred to an
immunobilon-P membrane. Unspeciﬁc binding of the an-
tibodies was prevented by soaking the membrane in PBS
buﬀer-tween 20 containing 5% of dried skimmed milk for
one hour at 37◦C. The membrane was then incubated
overnight at 4◦C with the function blocking monoclonal
antibody anti-rat CD11b (clone OX42) purchased from
Pharmingen and diluted to 1/1000 in TBS containing 1%
dried skimmed milk. Immunoreactive bands were revealed
using peroxidase conjugated anti-rat IgG antibodies.
3. RESULTS AND DISCUSSION
3.1. TheermE-uppromoterdrivesanefﬁcient
expressionoftheratαintegrinCD11b
A-domaininS.lividans
To investigate the potential of S. lividans 1326 to express
α integrin A-domain as a secreted recombinant protein,
the A-domain of the rat leukocyte β2 integrin αMs u b -
unit (CD11b), coding sequence was ampliﬁed by PCR and
fused to the long synthetic signal peptide (LSSP) [10]o f
the pMS51 plasmid harbouring the ermE-up promoter as
SacI
PermE
BamHI
+ pMS39 carrying LSSP
PermE from pIJ4070
pMS41
EcoRV
KpnI HincII
PermE LSSP
PermE-LSSP from pMS41
+ pIJ4070
A-domain PstI
Cloning in pCR
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pMS52
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A-domain from pMS52
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BglII BglII
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LSSP
A-domain
BglII
Figure 1:ConstructionofplasmidpMS115.TheconstitutiveermE-
up promoter from pIJ4070 was subcloned as a SacI-BamHI frag-
ment in the pMS39 plasmid carrying the long synthetic signal pep-
tide (LSSP) giving the pMS41 plasmid. Then the KpnI-HincII frag-
ment carrying PermE-up-LSSP from pMS41 was cloned in pIJ4070
yielding the pMS51 plasmid. PCR product of the rat CD11b A-
domain was cloned into the pCR-Blunt vector to produce the
pMS52 plasmid. The fragment EcoRV-PstI corresponding to the A-
domain from pMS52 was cloned in pMS51 giving the pMS62 plas-
mid. Finally, the BglII fragment from pMS62 carrying the cassette
“PermE-up-LSSP-A-domain” was cloned in the pIJ699 vector yield-
ing the pMS115 plasmid.
described in “Materials and Methods” (Figure 1). Finally
the cassette “PermE-up-LSSP-A-domain” was introduced in
S. lividans 1326 using the E. coli/S. lividans shuttle vector
pIJ699 [24] giving the pMS115 plasmid (Figure 1).
To demonstrate the successful expression of the A-
domain in S. lividans 1326/pMS115, RT-PCR was carried
out with RNA prepared from this strain at diﬀerent growth
phases (late exponential phase (36h), early stationary phase
(50h), and late stationary phase (60h)) and treated with
DNase. As it is shown in Figure 2, an expected 495bp frag-
ment internal to the A-domain was eﬀectively ampliﬁed and
presented throughout all the growth stage tested with the
same intensity. This observation conﬁrms the constitutivi-
ty of the erm-up promoter that governs the expression of
the A-domain. This ampliﬁcation results from the cDNA4 Journal of Biomedicine and Biotechnology
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Figure 2: RT-PCR analysis of the A-domain expression in S. livi-
dans 1326/pMS115. Lane 1: smart ladder molecular weight (MW)
marker (Eurogentec). Lanes 2, 3, and 4: RT-PCR performed with
cDNA synthesised from 2μg of RNA treated with DNase and pre-
pared from the S. lividans 1326/pMS115 strain grown on TSB
medium for 36h, 50h, and 60h, respectively. Lane 5: PCR per-
formed directly with 2μg of RNA treated with DNase (control).
obtained from A-domain messengers since no ampliﬁcation
was observed when PCR reaction was performed directly
withDNase-treatedRNA.Thisresultconﬁrmstheexpression
in S. lividans 1326/pMS115 of the rat αM subunit (CD11b)
A-domain sequence under the control of the constitutive
ermE-up promoter from Streptomyces erythraeus [22]. In-
deed, this strong and constitutive promoter was widely used
for gene expression in various Streptomyces species [10, 27–
31].
3.2. TheLSSPsignalpeptidepermitstheproduction
oftheCD11A-domainasanextracellularprotein
inS.lividans
The S. lividans 1326/pMS115 was grown for 48 hours on
NMMP medium with glucose as the carbon source. Then,
the supernatantculturewaslyophilized, dialyzed against PBS
buﬀer and electrophorized on an SDS polyacrylamide gel.
As shown in Figure 3, the size of the recombinant A-domain
(21kDa) expressed by S. lividans was the same of its homol-
ogous expressed in E. coli as a GST/A-domain fusion pro-
tein (48.5kDa) and released by thrombin cut [20]. Since it is
known that E. coli is unable to glycosylate the polypeptide,
and given the fact that the size of the recombinant protein
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Figure 3: Western blot analysis of the A-domain secretion in S.
lividans 1326/pMS115. Supernatant of the S. lividans 1326/pMS115
straingrownonNMMPmediumwasconcentrated50x,lyophilized,
resuspended in PBS, then dialyzed as described in “Materials and
Methods.” Proteins were run on a 15% SDS polyacrylamide gel.
Lane 1: molecular weight standards (MW) from Amersham; lane
2: 15μg of supernatant proteins from S. lividans 1326/pMS115; lane
3: 2μg of the recombinant A-domain (21kDa) released from the
GST/CD11b A-domain fusion protein (48.5kDa) by thrombin cut;
lane4:2μgoftheGST/CD11bA-domainfusionprotein(48.5kDa).
expressed in each system is similar, we can conclude that S.
lividans did not glysosylate the A-domain, even though the
sequence of the rat CD11b displays a putative N glycosyla-
tion site.
Furthermore, the yield of the recombinant rat CD11b
A-domain secreted by S. lividans was estimated at 8mg per
litre. This yield is based on the comparison of band inten-
sity as shown in Figure 3 and takes into consideration the
50x concentration of the supernatant prior to loading on
to electrophoresis gel. The estimated A-domain represents
8% of the total extracellular proteins (100mg/L). This rel-
atively low extracellular protein level could be explained by
the use of a minimal medium (NMMP) useful for the fur-
ther analysis. Western blot analysis of the supernatant of the
S. lividans culture showed (Figure 3)ap r o t e i nb a n dw i t ha
molecular mass of about 21kDa corresponding to the se-
creted rat CD11b A-domain expressed in S. lividans. Binding
of the function blocking antibody implied that this secreted
recombinant form is properly folded and suggests strongly
that the protein would be functional as previously shown
with its counterpart produced in E. coli.
As described by Mhiri et al. [10], the long synthetic
signal peptide (LSSP) contains two positive charges on the
N-terminal region and carries two ribosome binding sites
(RBS) as well as two translational initiation codons which
are known to contribute to increasing the yield of the se-
creted protein [15, 32]. This signal peptide was successfully
used for the secretion of the Streptomyces sp. TO1 amylaseDorra Zouari Ayadi et al. 5
[10]. The eﬃcient secretion in the S. lividans 1326/pMS115
culture supernatant of the A-domain of the rat leukocyte
αM subunit (CD11b) with the LSSP signal peptide argue in
favour of expanding the use of this signal peptide for secre-
tion of prokaryotic and eukaryotic proteins of interest in S.
lividans.TheabilitytoproducetheCD11A-domainasanex-
tra cellular protein is of great interest for performing further
structure-function studies as well as for applications of this
recombinant domain as potential anti-inﬂammatory agent.
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